Figure 1



BAL eosinophils
absolute eosinophils [*10^6]
3.0
2.5
2.0
1.5
1.0
0.5
0.0
42%
54%
*
77%
*
88%
PBS
OVA
3mg/kg tid
10mg/kg tid
30mg/kg tid
30mg/kg bid

Figure 2




Figure 3



% Inhibition of Eosinophil Shape Change
125
100
75
50
25
0
-25
-50
-75
-100
-125
1
10
100
1000
10000
plasma concentration (nmol/L)

Figure 4



125
100
75
50
25
0
-25
% Inhibition CCR3 Internalization
1
10
100
1000
10000
plasma concentration (nmol/L)

Figure 5



Skin Eosinophils
Mean Eosinophils per FOV
20
15
10
5
0
0
5
10
15
20
Days of Oxazolone Treatment

Figure 6



Blood Eosinophils
Eosinophils (x10^3 cells/ul)
0.15
0.10
0.05
0.00
0
5
10
15
20
Days oxazolone treated

Figure 7



Dryness score (out of 4)
0
1
2
3
4
0
7
8
9
10
11
12
13
14
15
16
17
18
19
Days oxazolone treated
Oxazolone
Oxazolone + Dexamethazone
Oxazolone + Compound 1
Control

Figure 8



Eosinophils (% of WBC)
1.5
1.0
0.5
0.0
****
***
****
****
***
*
**
Control
Oxazolone
Oxazolone + Compound 1
Oxazolone + delayed Compound 1
Oxazolone + Dexamethasone
Oxazolone + Compound 1 + Dexamethasone

Figure 9A



Lymphocytes (x10^3 cells/ul)
2.0
1.5
1.0
0.5
0.0
****
****
Control
Oxazolone
Oxazolone + Compound 1
Oxazolone + delayed Compound 1
Oxazolone + Dexamethasone
Oxazolone + Compound 1 + Dexamethasone

Figure 9B



WBC (x10^3 cells/ul)
4
3
2
1
0
**
**
Control
Oxazolone
Oxazolone + Compound 1
Oxazolone + delayed Compound 1
Oxazolone + Dexamethasone
Oxazolone + Compound 1 + Dexamethasone

FIGURE 10A




FIGURE 10B




FIGURE 10C




FIGURE 11A




FIGURE 11B

